Glioblastoma multiforme (GBM) is the most common and aggressive primary CNS cancer with a median survival of just 15 months. The incidence of GBM is 22,000 in the US and Europe combined. GBM is a difficult disease to treat and conventional treatment options have demonstrated limited responses. The survival of patients suffering from GBM has not improved significantly in the past three decades.
The current standard treatment consists of maximal safe resection, followed by radiation therapy and then maintenance chemotherapy.
Myc activity is frequently altered in GBMs (over half of cases).